What Ozone Pharmaceuticals does

Ozone Pharmaceuticals Limited, incorporated in 1991 and headquartered in New Delhi, is a privately held formulation pharmaceutical company operating as a core subsidiary of the diversified Ozone Group. The company manufactures and markets prescription drugs across 14 therapy areas — including pain management, cardio-diabetes, anti-infectives, nutritional supplements, vascular care, and hemostats — organized into three operating divisions: Proton for general therapeutics, Nucleus for women's health, and BLIP for critical care injectables.

Manufacturing is anchored by two ultramodern WHO-approved facilities located in Baddi (Himachal Pradesh) and Guwahati (Assam), supplemented by an NABL-accredited analytical testing laboratory in Gurugram (Delhi NCR) established in 2004. The Gurugram lab holds ISO 9001:2008/2015 certification, FSSAI recognition, FDA of Haryana approval, and Government of India approval under the Drugs and Cosmetic Act 1940, and also operates as a commercial third-party testing service. The R&D footprint is described as market-driven with a significant share of operating budget allocated to incremental formulation development rather than novel molecule discovery.

The business model is sales-led: a 1,000+ field force promotes products to 100,000+ specialist prescribers (cardiologists, diabetologists, orthopedics, gynecologists, surgeons, and physicians) across India and Nepal through a portfolio of 1,500+ marketed brands including DFO, Tranostat, Ozomet, Ozotel, Ozovas, and Ozopenem. Revenue is generated through prescription-channel sales via pharmacy distribution networks; pricing is not publicly disclosed and follows standard negotiated distributor economics. Adjacent revenue streams include commercial analytical testing services and the Ozone Professional Range cosmeceutical partnerships with Pevonia and Novex. The company is led by Chairman and Managing Director S.C. Sehgal, and the Ozone Group as a whole employs 1,500+ people across pharmaceuticals, beauty/cosmetics, food, wellness, and skill development.

Name

Ozone Pharmaceuticals

Legal name

Ozone Pharmaceuticals Limited

Website

https://ozonepharma.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ozone Pharmaceuticals Limited is a New Delhi-based privately held formulation pharmaceutical company, founded in 1991, that manufactures and markets prescription drugs across 14 therapy areas through three divisions (Proton, Nucleus, BLIP), targeting specialists across India and Nepal via a 1,000+ field sales force and a 1,500+ product portfolio.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Pharmaceutical manufacturing
• Prescription drugs
• Generic formulations
• Critical care injectables
• Women's health medicines

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Formulation-based drug manufacturing and marketing company focused on prescription drugs across 14 therapy areas including pain management, nutritional supplements, anti-infectives, vascular management, chronic disease management (cardiac and diabetes), and hemostats. Products marketed through Proton (general therapeutics), Nucleus (women's health), and BLIP (critical care) divisions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Ozone Pharmaceuticals Limited is a formulation-based pharmaceutical company that manufactures and markets prescription drugs across 14 therapy areas including pain management, nutritional supplements, anti-infectives, vascular management, chronic disease management (cardiac and diabetes), and hemostats. Products are organized into three divisions — Proton (general therapeutics), Nucleus (women's health), and BLIP (critical care) — manufactured at two WHO-approved facilities in Baddi, Himachal Pradesh and Guwahati, Assam, with quality testing at an NABL-accredited laboratory in Gurugram. The company sells its products through a 1,000+ person field sales force reaching over 100,000 doctors in India and Nepal.

Product overview

Ozone Pharmaceuticals is a formulation-based pharmaceutical company organized into three main divisions: Proton (general health and chronic disease management), Nucleus (women's health and nutritional supplements), and BLIP (critical care and injectables). The product portfolio spans 14 therapy areas including pain management, cardio-diabetes, antibiotics, nutritional supplements, and hemostats. Products are manufactured at WHO-approved facilities in Baddi and Guwahati, with quality testing conducted at NABL-accredited laboratories.

Differentiator

Problem solved

Functional benefit

Brands

• Proton: Division focused on extending a healing touch, covering hemorrhoid management, cardio-diabetes management, alcohol de-addiction, pediatric care, nutrition, cough care, and antibiotics.
• Nucleus
• BLIP

Products and services

• Proton Division General therapeutics division offering products for pain management, cardio-diabetes management, hemorrhoid management, antibiotics, cough care, and nutrition supplements, sold to prescribing physicians across India and Nepal.
• Nucleus Division Women's health division offering pregnancy care, blood loss management, iron and calcium supplementation, feminine hygiene, neurotropic vitamins, and gastro care products, targeted at gynecologists and women's health prescribers.
• BLIP Critical Care Division Critical care division offering general injectables, cephalosporin and penicillin antibiotics, carbapenem antibiotics, pre-filled syringes, IV infusions, and respiratory respule products for hospital and surgical use.
• DFO Gel Topical analgesic gel containing Oleum lini (alpha Linolenic acid), Diclofenac Diethylammonium, Methyl salicylate, and Menthol for pain relief, prescribed by orthopedics and general practitioners.
• DFO 4X Gel Topical analgesic gel with Diclofenac Sodium 1.6%, Oleum lini 3.0%, Methyl Salicylate 10%, and Menthol 1% for pain management.
• DYRECT Enteric coated tablet containing Diclofenac Potassium 50mg and Serratiopeptidase 10mg used for anti-inflammatory pain management.
• OZOMET Extended release Metformin Hydrochloride tablets for diabetes management, available in 500mg and combination formulations with Glimepiride and Pioglitazone.
• OZOTEL Telmisartan-based antihypertensive tablets available in plain, H (with Hydrochlorothiazide), AM (with Amlodipine), and AMH (triple combination) formulations for hypertension management.
• OZOVAS Atorvastatin tablets (10mg/20mg) for cholesterol management, also available in combination with Fenofibrate.
• PERFEKT Pantoprazole 40mg film-coated tablet for proton pump inhibition and gastroesophageal reflux management.
• Tranostat Tranexamic acid tablets (500mg) and injections for blood loss management and hemostasis.
• Ozored Iron supplementation tablets and suspension containing Ferrous ascorbate, Folic acid, and Zinc for anemia management.
• Ozowite Calcium citrate malate tablets with Vitamin D3 for calcium supplementation and bone health.
• Cynocal-16 Neurotropic vitamin complex available as tablets, injections, and syrup containing B vitamins, Magnesium, and Nicotinamide for nerve health management.
• Wanto Lact Herbal lactation support capsules containing Shatavari, Fenugreek, Vidarikand, and other botanical extracts.
• XPAND Amoxicillin 500mg and Clavulanic Acid 125mg combination antibiotic tablets for treating bacterial infections.
• OZOCEF Cefixime-based cephalosporin antibiotic for treating susceptible bacterial infections.
• OZOPENEM Carbapenem antibiotic for serious bacterial infections requiring broad-spectrum antimicrobial coverage.
• BLIPOLID IV IV infusion product for critical care and hospital use.
• BUDEOZ Respiratory respule product for inhalation therapy.
• OZOPARIN Pre-filled syringe product for subcutaneous administration.

Quantifiable outcome

• 1000+ clients served by analytical testing laboratory
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor.

• PevoniaminorChannel Partner/ Reseller/ DistributorOzone Professional Range tied up with Pevonia as their exclusive India partner for distribution of premium skin care products.
• NovexminorChannel Partner/ Reseller/ DistributorOzone Professional Range tied up with Novex as their exclusive India partner for distribution of hair care products.
• Sulabh International DelhiminorOthersOzone Mission collaborated with Sulabh International Delhi to run the Sulabh Toilet Complex - a public convenience complex with modern toilet facilities at Jatipura village, Govardhan, as part of CSR initiatives.
• Government of India (OSCAR)minorStrategic or Co-development PartnerPartnering with the Govt. of India, the group foray into skill development training focused on empowering urban and rural youth. OSCAR has been driving training in several trades like bedside patient attendant, sales and retail, beauty therapy and hairdressing.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mankind Pharma: Large Indian branded-generics manufacturer and marketer with deep field force across primary care and chronic disease (including cardiology-diabetes). Highly comparable domestic GTM model and therapy-area overlap (DFO ↔ Mankind analgesics; cardiometabolic cluster).
• Alkem Laboratories: Indian pharmaceutical manufacturer with strong field sales presence across gastro, cardio-diabetes, anti-infectives, and critical care — overlapping directly with Ozone's Proton, Nucleus, and BLIP divisions.
• Torrent Pharmaceuticals: Indian pharma manufacturer with strong specialty presence in cardiology-diabetes and women's health, two of the most prominent franchises in Ozone's product mix.
• Ipca Laboratories: Indian prescription pharma company with comparable API + formulation operations across pain, anti-infectives, and cardiovascular, well matched to Ozone's portfolio.
• Intas Pharmaceuticals: Privately held Indian pharma manufacturer with broad therapy-area prescription portfolio and significant hospital/critical-care business, mirroring Ozone's BLIP division focus.
• Eris Lifesciences: Mid-cap Indian pharma company specialized in chronic disease (cardio-diabetes, gynae, derma, neutraceuticals) — directly comparable to Ozone's Proton chronic-disease focus and Nucleus gynae division.

Broad incumbents

• Zydus Lifesciences: Large Indian pharma with prescription formulations across cardio-diabetes, women's health, and critical care injectables — overlapping therapy areas but operating at a far greater scale.
• Lupin: Large diversified Indian pharma manufacturer with substantial presence in cardiovascular, diabetes, anti-infectives, and women's health — overlapping Ozone's portfolio at much greater scale.
• Cipla: Among the largest Indian pharma incumbents with broad prescription (chronic + acute + hospital) portfolio and a much larger domestic field force; comparable therapy breadth though materially larger scale.

Regional players

• Hetero Labs: Large Indian API and formulation manufacturer with strong anti-infective and HIV/critical care franchises; comparable as a domestic manufacturer in overlapping antibiotic/injectable categories but with a much larger export footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ozonepharma

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ozone Pharmaceuticals